Moleculin Biotech Inc expected to post a loss of $2.44 a share - Earnings Preview

Moleculin Biotech

06/11/2024 23:22

* Moleculin Biotech Inc  MBRX.OQ   MBRX.O  is expected
to show no
change in quarterly revenue when it reports  results on November
8 for the period ending January 1 0001
    * 
    * ​LSEG's mean analyst estimate for Moleculin Biotech Inc is
for a
loss of $2.44 per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 3 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Moleculin
Biotech
Inc is $30.00​, above​ its last closing price of $2.30. ​​​

This summary was machine generated November 6 at 23:21 GMT.  All
figures in US dollars unless otherwise stated. (For questions
concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)